Porphyria and pseudoporphyria.
D000437:Alcoholism / Q000150:complications; D001815:Bloodletting; D005260:Female; D005665:Furosemide / Q000009:adverse effects; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D009268:Nalidixic Acid / Q000009:adverse effects; D011164:Porphyrias / Q000145:classification* / Q000209:etiology / Q000628:therapy; D012871:Skin Diseases / Q000145:classification* / Q000209:etiology / Q000628:therapy; D009626:Terminology as Topic; D013752:Tetracycline / Q000009:adverse effects
D009268:Nalidixic Acid; D006886:Hydroxychloroquine; D005665:Furosemide; D013752:Tetracycline